paroxysmal nocturnal hemoglobinuria

FDA approves Novartis' kidney disease drug
Reuters
Wed, 08/7/24 - 11:02 pm
Novartis
FDA
Fabhalta
kidney disease
paroxysmal nocturnal hemoglobinuria
Novartis receives FDA approval for Fabhalta to treat PNH in adults
Pharmaceutical Business Review
Wed, 12/6/23 - 10:25 am
Novartis
FDA
Fabhalta
iptacopan
PNH
paroxysmal nocturnal hemoglobinuria
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Endpoints
Thu, 12/8/22 - 10:37 am
Novartis
clinical trials
paroxysmal nocturnal hemoglobinuria
iptacopan
AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3
Fierce Biotech
Mon, 09/19/22 - 09:25 am
AstraZeneca
Alexion
danicopan
paroxysmal nocturnal hemoglobinuria
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Wed, 09/25/19 - 11:32 pm
Achillion
FDA
paroxysmal nocturnal hemoglobinuria
Soliris
PNH
Alexion runs toward big Ultomiris goals with early Soliris switching success
Fierce Pharma
Tue, 02/5/19 - 11:17 pm
Alexion
Ultomiris
paroxysmal nocturnal hemoglobinuria
PNH
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Mon, 08/20/18 - 11:40 am
Alexion Pharmaceuticals
Alexion
FDA
ALXN210
PNH
paroxysmal nocturnal hemoglobinuria
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
Mon, 08/20/18 - 09:59 am
Alexion Pharmaceuticals
paroxysmal nocturnal hemoglobinuria
ALXN1210
Alexion's follow-on stacks up to Soliris
Biopharma Dive
Fri, 03/16/18 - 11:19 am
Alexion
Soliris
ALXN1210
paroxysmal nocturnal hemoglobinuria
PNH